Literature DB >> 8781098

Perforation of the right aortic valve cusp: complication of ventricular septal defect closure with a modified Rashkind umbrella.

M Vogel1, M L Rigby, D Shore.   

Abstract

An 18-month-old boy with a perimembranous ventricular septal defect (VSD) had undergone transcatheter closure of the defect with a modified 17 mm Rashkind umbrella device at age 4 months (weight 3.8 kg). The clinical signs of a VSD persisted, and he developed aortic incompetence, first detected 5 months after the procedure, which progressed from mild to moderate. A three-dimensional echocardiographic study demonstrated that one of the four arms holding the umbrella was protruding into the aortic valve and had perforated the right aortic valve cusp. This diagnosis was confirmed at subsequent surgery. Surgical repair of the perforated right aortic valve leaflet was necessary. The umbrella was adherent to the tricuspid valve and could not be removed. Instead it was left in situ, but three of the stainless steel arms were cut off. When umbrella closure of a perimembranous VSD is undertaken, the close proximity of part of the distal umbrella to the aortic valve can lead to aortic regurgitation.

Entities:  

Mesh:

Year:  1996        PMID: 8781098     DOI: 10.1007/s002469900093

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  10 in total

1.  Ventricular Septal Defect.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

Review 2.  Catheter closure of perimembranous/membranous ventricular septal defects using the Amplatzer occluder device.

Authors:  B D Thanopoulos
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

3.  Transcatheter closure of perimembranous ventricular septal defect: is the risk of heart block too high a price?

Authors:  Ian D Sullivan
Journal:  Heart       Date:  2006-10-11       Impact factor: 5.994

4.  Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study.

Authors:  J Masura; W Gao; P Gavora; K Sun; A Q Zhou; S Jiang; L Ting-Liang; Y Wang
Journal:  Pediatr Cardiol       Date:  2005 May-Jun       Impact factor: 1.655

5.  Use of the Amplatzer muscular ventricular septal defect occluder for closure of perimembranous ventricular septal defects.

Authors:  M Szkutnik; S A Qureshi; J Kusa; E Rosenthal; J Bialkowski
Journal:  Heart       Date:  2006-09-15       Impact factor: 5.994

6.  Retrograde approach for device closure of muscular ventricular septal defects in children and adolescents, using the Amplatzer muscular ventricular septal defect occluder.

Authors:  Al-Ata Jameel; Amin Muhammed Arfi; Hussain Arif; Kouatli Amjad; Galal Mohammed Omar
Journal:  Pediatr Cardiol       Date:  2006-11-07       Impact factor: 1.655

7.  Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer asymmetric ventricular septal defect occluder: preliminary experience in children.

Authors:  B D Thanopoulos; G S Tsaousis; E Karanasios; N G Eleftherakis; C Paphitis
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

8.  Transcatheter device closure of perimembranous ventricular septal defects: mid-term outcomes.

Authors:  Jian Yang; Lifang Yang; Yi Wan; Jian Zuo; Jun Zhang; Wensheng Chen; Jun Li; Lijun Sun; Shiqiang Yu; Jincheng Liu; Tao Chen; Weixun Duan; Lize Xiong; Dinghua Yi
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

9.  A Large Institutional Study on Outcomes and Complications after Transcatheter Closure of a Perimembranous-Type Ventricular Septal Defect in 890 Cases.

Authors:  Jun Liu; Zhen Wang; Lei Gao; Hui-Lian Tan; Qinghou Zheng; Mi-Lin Zhang
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

10.  Transcatheter Device Closure of Perimembranous Ventricular Septal Defect in Pediatric Patients: Long-Term Outcomes.

Authors:  Jayal Hasmukhbhai Shah; Sanket Pravinchandra Saraiya; Tushar Sudhakarrao Nikam; Mukesh Jitendra Jha
Journal:  Heart Views       Date:  2020-01-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.